Human pluripotent stem cell (hPSC) derived cardiomyocytes were obtained by using our Monolayer Differentiation Protocol (see Application Note: Efficient generation of cardiomyocytes from human pluripotent stem cells) [ Ссылка ]. The differentiation protocol is based on the consecutive activation and inhibition of Wnt signaling. During the differentiation process cells start to cluster in order to form contracting areas as shown in the video recorded at an early stage of differentiation.
[ Ссылка ]
Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. Our more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 2,000 employees in 25 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.
